全文获取类型
收费全文 | 2725篇 |
免费 | 510篇 |
学科分类
医药卫生 | 3235篇 |
出版年
2024年 | 17篇 |
2023年 | 50篇 |
2022年 | 4篇 |
2021年 | 13篇 |
2020年 | 137篇 |
2019年 | 43篇 |
2018年 | 125篇 |
2017年 | 103篇 |
2016年 | 137篇 |
2015年 | 171篇 |
2014年 | 283篇 |
2013年 | 270篇 |
2012年 | 112篇 |
2011年 | 78篇 |
2010年 | 136篇 |
2009年 | 281篇 |
2008年 | 106篇 |
2007年 | 92篇 |
2006年 | 179篇 |
2005年 | 88篇 |
2004年 | 43篇 |
2003年 | 60篇 |
2002年 | 43篇 |
2001年 | 68篇 |
2000年 | 48篇 |
1999年 | 51篇 |
1998年 | 74篇 |
1997年 | 62篇 |
1996年 | 49篇 |
1995年 | 42篇 |
1994年 | 28篇 |
1993年 | 37篇 |
1992年 | 37篇 |
1991年 | 55篇 |
1990年 | 11篇 |
1989年 | 14篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1985年 | 9篇 |
1984年 | 11篇 |
1983年 | 3篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1980年 | 4篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1975年 | 9篇 |
1974年 | 3篇 |
1971年 | 2篇 |
排序方式: 共有3235条查询结果,搜索用时 15 毫秒
51.
Jocelyn F. Burke MD Logan Schlosser BS April D. Harrison BS Muthusamy Kunnimalaiyaan PhD Herbert Chen MD FACS 《Annals of surgical oncology》2013,20(12):3862-3868
Background
Development of targeted therapies for medullary thyroid cancer (MTC) has focused on inhibition of the rearranged during transfection (RET) proto-oncogene. Akt has been demonstrated to be a downstream target of RET via the key mediator phosphoinositide-3-kinase. MK-2206 is an orally administered allosteric Akt inhibitor that has exhibited minimal toxicity in phase I trials. We explored the antitumor effects of this compound in MTC.Methods
Human MTC-TT cells were treated with MK-2206 (0–20 μM) for 8 days. Assays for cell viability were performed at multiple time points with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). The mechanism of action, mechanism of growth inhibition, and production of neuroendocrine tumor markers were assessed with Western blot analysis.Results
MK-2206 suppressed MTC cell proliferation in a dose-dependent manner (p ≤ 0.001). Levels of Akt phosphorylated at serine 473 declined with increasing doses of MK-2206, indicating successful Akt inhibition. The apoptotic proteins cleaved poly (ADP-ribose) polymerase and cleaved caspase-3 increased in a dose-dependent manner with MK-2206, while the apoptosis inhibitor survivin was markedly reduced. Importantly, the antitumor effects of MK-2206 were independent of RET inhibition, as the levels of RET protein were not blocked.Conclusions
MK-2206 significantly suppresses MTC proliferation without RET inhibition. Given its high oral bioavailability and low toxicity profile, phase II studies with this drug alone or in combination with RET inhibitors are warranted. 相似文献52.
Zorcolo L Rosman AS Restivo A Pisano M Nigri GR Fancellu A Melis M 《Annals of surgical oncology》2012,19(9):2822-2832
Background
Complete pathologic response (CPR) after neoadjuvant chemoradiotherapy (combined modality treatment, CMT) for rectal cancer seems associated with improved survival compared to partial or no response (NPR). However, previous reports have been limited by small sample size and single-institution design.Methods
A systematic literature review was conducted to detect studies comparing long-term results of patients with CPR and NPR after CMT for rectal cancer. Variables were pooled only if evaluated by 3 or more studies. Study end points included rates of CPR, local recurrence (LR), distant recurrence (DR), 5-year overall survival (OS), and disease-free survival (DFS).Results
Twelve studies (1,913 patients) with rectal cancer treated with CMT were included. CPR was observed in 300 patients (15.6%). CPR and NPR patient groups were similar with respect to age, sex, tumor size, distance of tumor from the anus, and stage of disease before treatment. Median follow-up ranged from 23 to 46?months. CPR patients had lower rates of LR [0.7% vs. 2.6%; odds ratio (OR) 0.45, 95% confidence interval (CI) 0.22?C0.90, P?=?0.03], DR (5.3% vs. 24.1%; OR 0.15, 95% CI 0.07?C0.31, P?=?0.0001), and simultaneous LR?+?DR (0.7% vs. 4.8%; OR 0.32, 95% CI 0.13?C0.79, P?=?0.01). OS was 92.9% for CPR versus 73.4% for NPR (OR 3.6, 95% CI 1.84?C7.22, P?=?0.002), and DFS was 86.9% versus 63.9% (OR 3.53, 95% CI 1.62?C7.72, P?=?0.002).Conclusions
CPR after CMT for rectal cancer is associated with improved local and distal control as well as better OS and DFS. 相似文献53.
54.
55.
56.
The primary therapy of anal cancer is curative radiochemotherapy. Following a confirmed diagnosis the role of the surgeon is the treatment of local complications of anal cancer by securing bowel passage and protection of the perineum by laparoscopic placement of a preternatural anus or stoma. For patients with a persistent or recurrent tumor following radiochemotherapy a clear improvement in the oncological process can be achieved by surgical salvage therapy using an abdominoperineal rectum extirpation. However, this is accompanied by a high morbidity of up to 80%. Of particular importance here are disturbances in wound healing in the perineum; therefore, a primary myocutaneous flap surgery can be used to cover the perineal resection wound and the rate of disturbances in wound healing can be substantially reduced. 相似文献
57.
58.
59.
60.